Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TA-8995

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: TA-8995. Displaying page 1 of 1.
    EudraCT Number: 2012-005643-24 Sponsor Protocol Number: TA-8995-03 Start Date*: 2013-07-29
    Sponsor Name:Xention Limited
    Full Title: A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy
    Medical condition: Mild dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004935-22 Sponsor Protocol Number: TA-8995-303 Start Date*: 2020-10-01
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia
    Medical condition: mild dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005064-22 Sponsor Protocol Number: TA-8995-301 Start Date*: 2022-09-22
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN): A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Partici...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002687-41 Sponsor Protocol Number: TA-8995-AD-1 Start Date*: 2021-12-09
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carr...
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 10:11:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA